Supplementary Tables S1 to S5 and Supplemental Figures 1 to 15 from SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma

Shigeki Ito,Keiichi Moriya,Yasuko Kuribayashi-Hamada,Mariko Ishibashi,Hiroshi Handa,Koiti Inokuchi,Sakae Tanosaki,Yuta Kaito,Mika Sunakawa,Hiroki Sugimori,Junji Tanaka,Asako Tsubota,Norio Komatsu,Asaka Onodera,Hideto Tamura,Yutaka Tsukune,Toshio Asayama,Norina Tanaka,Makoto Sasaki,Takeshi Odajima,Ryōsuke Takahashi ,Yumiko Imai

doi:10.1158/1541-7786.22514517.v1

Abstract

<p>Table S1. Primer sequences Table S2. Patient characteristics in cell - surface SLAMF3 and CD138 expression analysis. Table S3. One hundred and sixty-eight gene sets that were significantly upregulated in SLAMF3-KMS34 cells compared with Î"SLAMF3 cells (NOM P-value <0.05, FDR q-value <0.20). Table S4. Core enrichment genes in MAPK/ERK signal-related gene sets which were significantly enriched in SLAMF3.KMS34 cells compared with Î"SLAMF3 cells. Table S5. Characteristics of MGUS and newly diagnosed MM patients. Figure S1. SLAMF3 expression in MM patients. Figure S2. Expression of cell markers CD38, CD138, CD34, CD45, CD19, and CD27 in SLAMF3high and SLAMF3low cell fractions of U266 cells. Figure S3. SLAMF3, SHP2, and GRB2 mRNA in MM cell lines and patient samples. Figure S4. Melphalan sensitivity and BrdU incorporation in MM cells treated with SHP2- and GRB2-specific siRNA and NSC87877. Figure S5. Enrichment plots for the gene sets in Supplementary Table S3 which were associated with survival and cell proliferation. Figure S6. SLAMF3 expression on MM cells induced gene expression associated with survival and cell proliferation. Figure S7. Soluble SLAMF3 (sSLAMF3) in MM patients and cell lines. Figure S8. Correlation of serum sSLAMF3 levels with the percentage of BM plasma and SLAMF3-positive cells, and serum IL-6 concentrations. Figure S9. Receiver operating characteristics (ROC) curve for predicting the R-ISS score (I vs. II/ III) for patients with MM. Figure S10. Effect of soluble SLAMF3 on MM cells. Figure S11. Receiver operating characteristics (ROC) curve (ROC) curve Receiver operating characteristics (ROC) curve for predicting the R-ISS score (I vs. II/ III) for patients with MM. Figure S12. Effect of soluble SLAMF3 on MM cells. Figure S13. Proposed mechanism of disease progression via SLAMF3 signaling in MM. Figure S14. Expression of cell markers CD38, CD138, CD34, CD45, CD19, CD27 and c -kit in SLAMF3high and SLAMF3low cell fractions of U266 cells. Figure S15. Characteristics of SLAMF3high and SLAMF3low U266 cells.</p>

Full Text